DICLOPHENAC POTASSIUM VERSUS CEPHTAZIDIME FOR REDUCTION OF POST ERCP PANCREATITIS IN AVERAGE RISK PATIENTS-RANDOMISED DOUBLE BLIND CONTROLLED TRIAL



This item was part of UEG Week 2015